Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stimuvax in rectal cancer during neoadjuvant chemoradiotherapy
NL-OMON38235Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2012
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tecemotide and cyclophosphamide in rectal adenocarcinoma and rectal cancer, sponsored by Merck & Co. Primary endpoints: Intratumoral immune response, Peripheral MUC1-specific immune response and 1 more. Started Apr 2012; status: active, not recruiting.
02
Drugs
tecemotidecyclophosphamide
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on NL-OMON38235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38235.